CITIUS ONCOLOGY, INC. 8K

Citius Oncology reported strong early commercial traction for LYMPHIR, with rapidly growing institutional uptake, formulary inclusion, and payer coverage supporting anticipated revenue growth in the CTCL market.

On August 5, 2026, Citius Oncology, Inc. announced a commercial update for its FDA‑approved CTCL therapy LYMPHIR (denileukin diftitox‑cxdl), highlighting a 78% quarter‑over‑quarter increase in new U.S. institutional accounts ordering the product, a 31% rise in institutional vial orders for the quarter ended June 30, 2026, expanding formulary adoption and near‑universal payer coverage, and management’s expectation of continued growth in institutional access, scientific engagement with CTCL experts, and topline revenue as the company targets broader penetration of an estimated $400+ million initial CTCL market.

Filing Facts

CIK

1851484

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-085434

Alert Tier

6